Company: TVRD
Filing Date: 2025-10-07
Form Type: S-1/A
Source: 0001104659-25-097519
Chunk: 268

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-07
Form: S-1/A
Chunk 268
---
 January 2023, VFMCRP and Winhealth Pharma signed a long-term exclusive licensing agreement for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China.

<div align='center'>157</div>

Vifor Fresenius Medical Care Renal Pharma Ltd. paid Cara $0 and $414,885 pursuant to the Fresenius Agreement for the fiscal years ended December 31, 2024 and 2023, respectively. In addition, no amounts were paid to Cara pursuant to the Fresenius Agreement. In addition, no amounts were paid to Cara pursuant to the Fresenius Agreement following the fiscal year ended December 31, 2024 through the date the agreement was terminated. The Fresenius Agreement was terminated upon consummation of the Asset Disposition. Fresenius Supply Agreement In connection with Fresenius Agreement, Cara also had a related supply agreement with Vifor Fresenius Medical Care Renal Pharma Ltd. (the “Fresenius Supply Agreement”), pursuant to which Cara retained the right to make and have made KORSUVA (difelikefalin) injection worldwide (excluding the United States, Japan and South Korea) (the “Territory”) for commercial sale by Vifor Fresenius Medical Care Renal Pharma Ltd. in or outside the Territory, and for supply of KORSUVA (difelikefalin) injection to Vifor Fresenius Medical Care Renal Pharma Ltd. The supply price was Cara’s COGS, as calculated under U.S. GAAP, plus an agreed upon margin. Vifor Fresenius Medical Care Renal Pharma Ltd. paid Cara $0 pursuant to the Fresenius Supply Agreement for each of the fiscal years ended December 31, 2024 and 2023. In addition, no amounts were paid to Cara pursuant to the Fresenius Supply Agreement following the fiscal year ended December 31, 2024 through the date the agreement was terminated. The Fresenius Supply Agreement was terminated upon consummation of the Asset Disposition. Asset Purchase Agreement On December 17, 2024, Cara and its subsidiary, Cara Royalty Sub, LLC (“Royalty Sub”, and together with us, each, a “Seller” and together, the “Sellers”), entered into an Asset Purchase Agreement (“APA”) with VFMCRP, pursuant to which, on April